Precision BioSciences receives "buy" ratings from HC Wainwright and Guggenheim with $60 and $19 price targets.
Precision BioSciences (NASDAQ:DTIL) has received a "buy" rating from HC Wainwright, with a $60.00 price target indicating a potential upside of 399.17% from the company's previous close. Guggenheim also issued a "buy" rating and a $19.00 target price on the stock. Precision BioSciences currently has a market capitalization of $83.13 million, a PE ratio of -1.61, and a beta of 1.62.
May 16, 2024
3 Articles